Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of concomitant Gardasil and bivalent rLP2086 vaccination in healthy adolescents
2013-002137-38Phase 2
- Sponsor
- Pfizer
- Start
- May 2013
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in meningococcal disease and human papillomavirus infection comparing Gardasil + bivalent rLP2086 vaccine, bivalent rLP2086 vaccine alone and Gardasil alone (3 arms). Primary endpoints: Geometric mean titers for 4 HPV antigens after Gardasil vaccination, Noninferiority of Gardasil immune response when coadministered with bivalent rLP2086 vaccine and 1 more.
02
Drugs
qHPV vaccinemeningococcal group B recombinant lipoprotein 2086 vaccine
03
Conditions
meningococcal diseasehuman papillomavirus infection
Beyond the preview
Go deeper on 2013-002137-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002137-38.